PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.88%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-27.70%
Negative operating expenses growth needs verification. Benjamin Graham would examine sustainability.
-27.70%
Negative total costs growth needs verification. Benjamin Graham would examine sustainability.
-8.45%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
No Data
No Data available this quarter, please select a different quarter.
27.70%
EBITDA growth above 15% demonstrates exceptional operating performance. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
27.70%
Operating income growth above 15% demonstrates exceptional core profitability. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
117.18%
Tax expense growth above 20% signals concerning expansion. Seth Klarman would scrutinize tax strategy.
-117.18%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-117.27%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-117.27%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.